A detailed history of Armistice Capital, LLC transactions in Fibrogen Inc stock. As of the latest transaction made, Armistice Capital, LLC holds 6,800,000 shares of FGEN stock, worth $2.38 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
6,800,000
Previous 8,936,000 23.9%
Holding current value
$2.38 Million
Previous $7.95 Million 65.8%
% of portfolio
0.05%
Previous 0.1%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.33 - $1.26 $704,880 - $2.69 Million
-2,136,000 Reduced 23.9%
6,800,000 $2.72 Million
Q2 2024

Aug 14, 2024

BUY
$0.89 - $2.36 $890,000 - $2.36 Million
1,000,000 Added 12.6%
8,936,000 $7.95 Million
Q1 2024

May 15, 2024

SELL
$0.73 - $2.73 $1.33 Million - $4.99 Million
-1,828,000 Reduced 18.72%
7,936,000 $18.6 Million
Q4 2023

Feb 13, 2024

BUY
$0.38 - $0.91 $711,360 - $1.7 Million
1,872,000 Added 23.72%
9,764,000 $8.69 Million
Q3 2023

Nov 14, 2023

BUY
$0.79 - $2.83 $2.79 Million - $10 Million
3,536,000 Added 81.18%
7,892,000 $6.79 Million
Q2 2023

Aug 14, 2023

BUY
$2.49 - $20.59 $5.09 Million - $42.1 Million
2,044,000 Added 88.41%
4,356,000 $11.8 Million
Q1 2023

May 15, 2023

SELL
$15.95 - $25.18 $24.8 Million - $39.1 Million
-1,552,000 Reduced 40.17%
2,312,000 $43.1 Million
Q4 2022

Feb 14, 2023

SELL
$13.27 - $17.73 $7.86 Million - $10.5 Million
-592,000 Reduced 13.29%
3,864,000 $61.9 Million
Q3 2022

Nov 14, 2022

BUY
$11.4 - $14.6 $4.15 Million - $5.31 Million
364,000 Added 8.9%
4,456,000 $58 Million
Q2 2022

Aug 15, 2022

BUY
$7.94 - $12.96 $32.5 Million - $53 Million
4,092,000 New
4,092,000 $43.2 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.